Cargando…
S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428444/ http://dx.doi.org/10.1097/01.HS9.0000968108.98119.51 |
| _version_ | 1785090470798426112 |
|---|---|
| author | Shi, Yan Zhou, Hu Huang, Ruibin Wang, Fang Mei, Heng Lin, Lie Guo, Jingming Zhou, Xin LI, Zhenyu Liu, Yaorong LI, Sichen Zhou, Wei Hou, Ming |
| author_facet | Shi, Yan Zhou, Hu Huang, Ruibin Wang, Fang Mei, Heng Lin, Lie Guo, Jingming Zhou, Xin LI, Zhenyu Liu, Yaorong LI, Sichen Zhou, Wei Hou, Ming |
| author_sort | Shi, Yan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428444 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284442023-08-17 S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY Shi, Yan Zhou, Hu Huang, Ruibin Wang, Fang Mei, Heng Lin, Lie Guo, Jingming Zhou, Xin LI, Zhenyu Liu, Yaorong LI, Sichen Zhou, Wei Hou, Ming Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428444/ http://dx.doi.org/10.1097/01.HS9.0000968108.98119.51 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Shi, Yan Zhou, Hu Huang, Ruibin Wang, Fang Mei, Heng Lin, Lie Guo, Jingming Zhou, Xin LI, Zhenyu Liu, Yaorong LI, Sichen Zhou, Wei Hou, Ming S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY |
| title | S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY |
| title_full | S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY |
| title_fullStr | S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY |
| title_full_unstemmed | S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY |
| title_short | S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY |
| title_sort | s299: orelabrutinib, an irreversible inhibitor of bruton’s tyrosine kinase, for treatment of primary immune thrombocytopenia: results of a randomized, open-label phase ii study |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428444/ http://dx.doi.org/10.1097/01.HS9.0000968108.98119.51 |
| work_keys_str_mv | AT shiyan s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT zhouhu s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT huangruibin s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT wangfang s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT meiheng s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT linlie s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT guojingming s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT zhouxin s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT lizhenyu s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT liuyaorong s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT lisichen s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT zhouwei s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy AT houming s299orelabrutinibanirreversibleinhibitorofbrutonstyrosinekinasefortreatmentofprimaryimmunethrombocytopeniaresultsofarandomizedopenlabelphaseiistudy |